Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations EYSINS, Switzerland--(Healthcare Sales & Marke... Biopharmaceuticals, RegulatoryVertex Pharmaceuticals, KALYDECO, ivacaftor, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news